Table 4. Comparing of the disease-free survival, metastasis-free survival and overall survival between untreated early breast cancer patients that presented high expression and those with negative/low expression of CD105.

Clinical data	High expression *	Negative/low expression *
Disease-free survival	70.64±15.40 (a)	132.01±7.62 (a)
Metastasis-free survival	81.73±15.45 (b)	136.11±6.66 (b)
Overall survival	96.62±15.51 (c)	143.58±4.42 (c)

* The data are expressed in months as mean±standard error. The p-value of a, b and c is 0.0010 [Kaplan-Meier method and analyzed by log-rank (Mantel-Cox)-test]. The adjusted p-value of a, b and c is 0.0327 (Benjamini-Hochberg correction)